CTLA4 and cancer: Interestingly, while CTLA-4 is a relevant target to enhance effector responses during cancer in some tumor models (33, 40), blockade of CTLA-4 results in enhanced costimulatory signals and hyperproliferation of Treg cells which drove increased immune tolerance (41).